Premium
Hydrophilic Polymer Drug from a Derivative of Salicylic Acid: Synthesis, Controlled Release Studies and Biological Behavior
Author(s) -
Rodríguez Gema,
Gallardo Alberto,
Fernández Mar,
Rebuelta Mercedes,
Buján Julia,
Bellón Juan M,
Honduvilla Natalio G,
Escudero Cristina,
San Román Julio
Publication year - 2004
Publication title -
macromolecular bioscience
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.924
H-Index - 105
eISSN - 1616-5195
pISSN - 1616-5187
DOI - 10.1002/mabi.200400015
Subject(s) - copolymer , chemistry , biocompatibility , polymer chemistry , monomer , polymer , drug delivery , drug carrier , macromolecule , organic chemistry , biochemistry
Summary: Hydrophilic polymeric drugs bearing “Triflusal” (4‐trifluoromethylsalicylic acid), a drug widely used as antithrombogenic agent (Disgren®), have been prepared by free radical copolymerization of methacryloyloxyethyl [2‐(acetyloxy)‐4‐(trifluoromethyl)] benzoate (HTRF) and N , N ′‐dimethylacrylamide (DMA). The reactivity ratios of both monomers have been determined by 1 H NMR spectra by applying non‐linear least square treatments to the copolymerization equation (terminal model), and the kinetic parameters obtained indicated that the microstructure of copolymer chains is homogeneous, with a random distribution of the active HTRF units along the copolymer chains. That means that for the copolymer system THDMA22 used in this work, HTRF units are mainly isolated in relatively long DMA sequences. Therefore, in this structure the intramolecular interactions between adjacent HTRF units are negligible. Release of Triflusal from THDMA22 has been studied in vitro using buffered solutions at pH = 2, 7.4 and 10 and 37 °C. The system showed an interesting pseudo‐zero order release profile at pH = 7.4 during several months. It has been also evaluated the pharmacological activity and the behavior of the system in contact with biological media. In this sense, we have carried out some in vitro studies about the antiaggregant properties and biocompatibility of THDMA22. Results demonstrate that this copolymer inhibits platelet aggregation in its macromolecular form and presents a good biocompatibility with Human Osteoblastic Cells (HOS).The Figure shows the drug release from THDMA22 at pH = 2 (⋄), 7.4 (□) and 10 (▵).